Targets › ATP7A
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2031.
ATP-driven copper (Cu(+)) ion pump that plays an important role in intracellular copper ion homeostasis. Within a catalytic cycle, acquires Cu(+) ion from donor protein on the cytoplasmic side of the membrane and delivers it to acceptor protein on the lumenal side. (UniProt, Q04656)
Open in Phaseline: the race on ATP7A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dartmouth-Hitchcock Medical Center | Tetrathiomolybdate (TM) Copper-lowering agent that forms stable copper-molybdenum clusters, sequestering copper an | ATP7A, ATP7B | Phase 1 | Triple Negative Breast Cancer | Jun 2031 |
Triple Negative Breast Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.